Veliparib (ABT-888) is an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor that AbbVie is evaluating in multiple tumor types.6,7
Proposed Mechanism of Action
Proteins of the PARP family are naturally occurring enzymes in human cells that are critical to the repair of single-strand DNA breaks.6,7 While this is a useful process to maintain the integrity of healthy cells, the same process can also repair chemotherapy-induced DNA damage in cancer cells that may have limited capacity for repairing double-strand DNA breaks.7,8 Veliparib is designed to inhibit PARP1 and PARP2, potentially leading to the accumulation of single-strand and double-strand DNA breaks in tumor cells that may have limited capacity for DNA repair, which results in chromosomal instability, cell cycle arrest, and subsequent apoptosis.6,7,9
Veliparib is being developed in settings where it can be combined with common DNA-damaging therapies like chemotherapy or radiation.6,7,10-13 It is in clinical trials for the treatment of patients with BRCA-deficient breast cancer, ovarian cancer, and lung cancer, as well as a number of other cancer types.
View select clinical trials with veliparib now. To view a full list of clinical trials in which veliparib is being investigated, please visit ClinicalTrials.gov.
Veliparib (ABT-888) is an investigational drug that is for clinical study only. Safety and efficacy have not been established.